REGN Surges 2.27% on Strong Dupixent Sales, Ranks 119th in $780M Volume Amid Eylea HD Slump

On August 4, 2025, Regeneron Pharmaceuticals (REGN) surged 2.27% with a trading volume of $0.78 billion, ranking 119th in market activity. The biotech firm reported Q2 adjusted earnings of $12.89 per share, exceeding estimates, driven by robust sales of Dupixent and Eylea HD. Revenue rose 4% year-over-year to $3.68 billion, with Eylea HD U.S. sales increasing 29% to $393 million. However, total Eylea HD and Eylea U.S. sales fell 25% to $1.15 billion amid competitive pressures and manufacturing delays at Novo Nordisk-owned Catalent, which impacted FDA review timelines for Eylea HD.

Analysts raised price targets following the earnings beat, with Guggenheim increasing its target to $815 from $810 and RBC Capital to $695. Management highlighted a strategic shift toward late-stage opportunities in high-unmet-need areas, contrasting prior focus on early-stage assets. Despite manufacturing challenges, Dupixent sales grew 22% globally to $4.34 billion, while Lynozyfic received FDA approval for multiple myeloma. The company downplayed potential tariff impacts, citing minimal expected disruption to its operations.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day yielded a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This highlights the significance of liquidity concentration in short-term performance, particularly in volatile markets, where institutional and algorithmic trading activity can amplify price movements in high-volume stocks.